Cat. No. 5355
Chemical Name: N-[3-Chloro-4-[[[2-(methylamino)-6-
Biological ActivityPotent and selective GPR39 agonist (EC50 values are 0.4 and 0.8 nM for rat and human receptors respectively). Selective over a panel of kinases (IC50s > 10 μM) and displays minimal binding affinity for ghrelin and neurotensin-1 receptors (IC50s > 30 μM). Increases GLP-1 levels in vitro and in vivo. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Peukert et al (2014) Discovery of 2-pyridylpyrimidines as the first orally bioavailable GPR39 agonists. ACS Med.Chem.Lett. 5 1114. PMID: 25313322.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for TC-G 1008 include:
Mlyniec et al (2016) Potential antidepressant-like properties of the TC G-1008, a GPR39 (zinc receptor) agonist. J Affect Disord. 201 179. PMID: 27235821.
Do you know of a great paper that uses TC-G 1008 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: TC-G 1008, supplier, TC-G1008, potent, selective, GPR39, agonists, agonism, Tocris Bioscience, Orphan 7-TM Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Potent dual CRTH2 and prostaglandin D2 (PGD2) receptor antagonistAM 4668
Potent FFA1 (GPR40) agonistCATPB
FFA2 antagonist/inverse agonistOleanolic acid
Selective GPBA receptor (TGR5) partial agonistPPTN hydrochloride
High affinity and selective P2Y14 antagonistItraconazole
SMO antagonist; acts at different binding site to cyclopamine (Cat No. 1623)SAR 216471 hydrochloride
Potent P2Y12 antagonist; orally availableA 971432
Potent and selective S1P5 agonistGLPG 0974
Potent FFA2 antagonistOgerin
Selective positive allosteric modulator at GPR68BGC 20-1531 hydrochloride
High affinity and selective EP4 antagonistMontelukast sodium
CysLT1 and GPR17 antagonist
October 30 - November 3, 2016
Boston, MA, USA